États-Unis · Plateformes & données · MarketBeat

HLS Therapeutics Targets 2027 Growth With Cardiovascular Expansion and New Deals

Publié par MarketBeat · États-Unis il y a 1 h

HLS Therapeutics (TSE:HLS) outlined plans to build on its cardiovascular portfolio and pursue additional business-development opportunities as the specialty pharmaceutical company…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

HLS Therapeutics Targets 2027 Growth With Cardiovascular Expansion and New Deals

À lire aussi

Australia's Q3 PPI rises 1.1% Q/Q; annual producer inflation holds steady at 3.6%

These 2 Nearly 100% Historically Accurate Market Signals Are Conflicting. Here's What Investors Should Do.

BYD shares dip as Q3 earnings disappoint

What gave this city its ‘best place to retire’ crown? You can actually afford to live there.

Sify (SIFY) Q2 2027 Earnings Call Transcript

Vigonvita Investors Extend Share Lock‑Up to Signal Long‑Term Confidence

HLS Therapeutics Targets 2027 Growth With Cardiovascular Expansion and New Deals

Partager

À lire aussi

Australia's Q3 PPI rises 1.1% Q/Q; annual producer inflation holds steady at 3.6%

These 2 Nearly 100% Historically Accurate Market Signals Are Conflicting. Here's What Investors Should Do.

BYD shares dip as Q3 earnings disappoint

What gave this city its ‘best place to retire’ crown? You can actually afford to live there.

Sify (SIFY) Q2 2027 Earnings Call Transcript

Vigonvita Investors Extend Share Lock‑Up to Signal Long‑Term Confidence